Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(38%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
1
13%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(5)

Detailed Status

Completed5
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

completed563%
recruiting338%

Recent Activity

3 active trials
Showing 5 of 8
recruitingphase_2

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

NCT07671924
completedphase_1

NAL ER IPF Respiratory Function and Safety Study

NCT07036029
recruitingphase_3

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
completedphase_2

Cough Reduction in IPF With Nalbuphine ER

NCT05964335
completedphase_2

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

NCT05962151
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07671924Phase 2

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

Recruiting
NCT07036029Phase 1

NAL ER IPF Respiratory Function and Safety Study

Completed
NCT07671911Phase 3

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Recruiting
NCT05964335Phase 2

Cough Reduction in IPF With Nalbuphine ER

Completed
NCT05962151Phase 2

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Completed
NCT07487740Phase 1

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

Recruiting
NCT07015398Phase 1

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Completed
NCT04030026Phase 2

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8